Biocon Pharma Company Profile
What is the competitive landscape for BIOCON PHARMA
BIOCON PHARMA has thirty-one approved drugs.
There are six tentative approvals on BIOCON PHARMA drugs.
Summary for Biocon Pharma
| US Patents: | 0 |
| Tradenames: | 27 |
| Ingredients: | 27 |
| NDAs: | 31 |
| PTAB Cases with Biocon Pharma as petitioner: | See PTAB cases with Biocon Pharma as petitioner |
Drugs and US Patents for Biocon Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biocon Pharma | PRAVASTATIN SODIUM | pravastatin sodium | TABLET;ORAL | 209869-001 | Apr 13, 2018 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Biocon Pharma | LIOTHYRONINE SODIUM | liothyronine sodium | TABLET;ORAL | 218070-003 | Feb 6, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Biocon Pharma | DASATINIB | dasatinib | TABLET;ORAL | 217217-002 | Mar 3, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
